Skip to content

June 2026

Default mode network

What June 2026's 6 new studies found, synthesized from the papers below. All Default mode network research →

The synthesis

Synthesized from 2 studies in the library · AI-generated, grounded in the abstracts below

Found by searching the library for Default mode network, DMN, resting-state network, then ranked by relevance.

Research in June 2026 found that psychedelics (psilocybin, MDMA, LSD) consistently attenuate bottom-up signal flow and directionality within the default mode network (DMN) in both humans and mice, as shown by a multi-dataset analysis. One study also reported opposite reconfigurations of hierarchical brain dynamics between psilocybin and escitalopram in depression, suggesting distinct DMN-related mechanisms. However, the evidence is limited by small sample sizes, reliance on open-label or single-dose designs, and a lack of long-term follow-up data.

Confidence in the evidence

Low-Moderate
  • Only two studies directly examined DMN effects of psychedelics in June 2026, with one being a multi-dataset analysis (article 27746) and the other a single RCT (article 27705).
  • The multi-dataset study (27746) included both human and animal data, but sample sizes per dataset were not specified, and the RCT (27705) had a moderate sample size (N not stated in abstract).
  • Both studies show consistent direction (attenuation/disruption of DMN hierarchical processing), but the evidence base is narrow and lacks replication across independent labs.
  • No studies in June 2026 addressed long-term durability of DMN changes or clinical outcomes beyond acute effects.
How we rate confidence

Confidence reflects the strength of the underlying evidence, not whether the result is favorable. It weighs the number and size of studies, their design (randomized trials count for more than observational or single-case work), how consistently they point the same way, and their risk of bias.

Tiers run from Insufficient to High. High is rare in this field: small, early, or open-label studies land lower even when their direction is encouraging.

Evidence by study

Direction is each study's finding relative to your question: Supports, Opposes, No effect, Mixed, or Unclear.

Distinct brain responses to psilocybin and escitalopram in depression captured by the Fluctuation-Dissipation Theorem 2026
Mixed

Psilocybin and escitalopram produced opposite reconfigurations of hierarchical non-equilibrium brain dynamics, with baseline measures distinguishing responders from non-responders.

double-blind randomized controlled trial

Psychedelics disrupt hierarchical cortical propagations in the default mode network of humans and mice. 2026
Supports

Psychedelics (MDMA, psilocybin, LSD) consistently attenuated bottom-up signal flow magnitude and directionality within the DMN across all drug-vs-control contrasts.

observational (multi-dataset analysis)

Points of agreement

  • Both studies indicate that psychedelics disrupt or reconfigure hierarchical processing within the DMN.
  • The attenuation of bottom-up DMN propagations is consistent across multiple psychedelic compounds and species.

Conflicts

  • Article 27705 found opposite DMN-related effects between psilocybin and escitalopram, while article 27746 focused only on psychedelics and did not compare to antidepressants.
  • The specific direction of DMN change (e.g., increased vs. decreased hierarchical processing) may differ depending on the analytical approach (FDT vs. optical flow).

Gaps

  • No studies examined long-term durability of DMN changes beyond acute drug effects.
  • Sample sizes were not reported for the multi-dataset analysis, limiting assessment of statistical power.
  • No studies in June 2026 directly linked DMN changes to clinical outcomes in patient populations.
  • The role of dose, route of administration, and individual differences (e.g., personality, baseline DMN connectivity) remains unexplored.
Browse these studies in the library